Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Mitglied/er, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
-
2024 WS
Vergangene Veranstaltungen (max. 10)
-
2024 SS
-
2023 WS
-
2023 SS
-
2022 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological InpatientsIn: Cancers Jg. 15 (2023) Nr. 11, 3029Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapyIn: Lung Cancer Jg. 178 (2023) S. 237 - 246Online Volltext: dx.doi.org/
-
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPALIn: Breast Cancer Research and Treatment Jg. 198 (2023) Nr. 3, S. 545 - 553Online Volltext: dx.doi.org/ (Open Access)
-
Übersicht über die aktuelle Studienlage beim EndometriumkarzinomIn: Die Onkologie Jg. 29 (2023) Nr. 5, S. 444 - 446Online Volltext: dx.doi.org/
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 - 44Online Volltext: dx.doi.org/ (Open Access)
-
Therapie des metastasierten MammakarzinomsIn: Der Onkologe Jg. 28 (2022) Nr. Suppl. 1, S. 61 - 63Online Volltext: dx.doi.org/
-
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase InhibitorsIn: Oncology Research and Treatment Jg. 44 (2021) Nr. 7-8, S. 400 - 407Online Volltext: dx.doi.org/ (Open Access)
-
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal CancerIn: JAMA Network Open Jg. 3 (2020) Nr. 3, S. e200643Online Volltext: dx.doi.org/ (Open Access)
-
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expressionIn: Cancer Medicine Jg. 9 (2020) Nr. 13, S. 4527 - 4539Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology (2020)Online Volltext: dx.doi.org/ (Open Access)
-
VicTORia : a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancerIn: Breast Cancer Research and Treatment Jg. 176 (2019) Nr. 3, S. 637 - 647Online Volltext: dx.doi.org/
-
Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer : Final results from the randomized phase II trial VicTORiaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii94Online Volltext: dx.doi.org/ (Open Access)
-
Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms : Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 2 mit Empfehlungen zur Therapie des primären, rezidivierten und fortgeschrittenen MammakarzinomsIn: Geburtshilfe und Frauenheilkunde Jg. 78 (2018) Nr. 11, S. 1056 - 1088Online Volltext: dx.doi.org/ (Open Access)
-
Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms : Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 1 mit Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des MammakarzinomsIn: Geburtshilfe und Frauenheilkunde Jg. 78 (2018) Nr. 10, S. 927 - 948Online Volltext: dx.doi.org/ (Open Access)
-
Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany : Interim results of the INGE-B phase II studyIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii111Online Volltext: dx.doi.org/ (Open Access)
-
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancerIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 36 (2018) Nr. 5, S. 848 - 859Online Volltext: dx.doi.org/ (Open Access)
-
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer : efficacy, safety and prognostic parametersIn: Journal of Cancer Research and Clinical Oncology Jg. 143 (2017) Nr. 10, S. 2131 - 2141Online Volltext: dx.doi.org/
-
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer : final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialIn: Breast Cancer Research and Treatment Jg. 156 (2016) Nr. 1, S. 97 - 107Online Volltext: dx.doi.org/ (Open Access)
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerIn: Annals of Oncology Jg. 27 (2016) Nr. 11, S. 2046 - 2052Online Volltext: dx.doi.org/ (Open Access)
-
Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)In: Cancer Research Jg. 76 (2016) Nr. Suppl. 4,Online Volltext: dx.doi.org/
-
Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 141 (2015) Nr. 1, S. 87 - 92Online Volltext: dx.doi.org/
-
Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)In: Cancer Research Jg. 75 (2015) Nr. 9 Suppl., S. PD2 - 4Online Volltext: dx.doi.org/
-
Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy : A Case Report and Review of the LiteratureIn: American Journal of Perinatology Reports Jg. 4 (2014) Nr. 1, S. 017 - 022Online Volltext: dx.doi.org/ (Open Access)
-
Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancerIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. e22032Online Volltext: dx.doi.org/
-
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013 : The German PerspectiveIn: Breast Care Jg. 9 (2014) Nr. 1, S. 52 - 59Online Volltext: dx.doi.org/
-
13th St. Gallen International Breast Cancer Conference 2013 : Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)In: Breast Care Jg. 8 (2013) Nr. 3, S. 221 - 229Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 15, S. 3076 - 3082Online Volltext: dx.doi.org/
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment Jg. 142 (2013) Nr. 1, S. 81 - 88Online Volltext: dx.doi.org/
-
Primary efficacy endpoint analysis of the CARIN trial : Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC)In: Cancer Research Jg. 73 (2013) Nr. Suppl. 24, P3-13-01Online Volltext: dx.doi.org/
-
ABC1 Consensus Conference – a German Perspective : First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011In: Breast Care Jg. 7 (2012) Nr. 1, S. 52 - 59Online Volltext: dx.doi.org/
-
Aktuelle Therapiestrategien beim metastasierten MammakarzinomIn: TumorDiagnostik & Therapie Jg. 33 (2012) Nr. 2, S. 86 - 89Online Volltext: dx.doi.org/
-
Trends in survival of patients with metastatic breast cancerIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 187
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 204 - 204
-
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancerIn: Annals of Oncology Jg. 22 (2011) Nr. 3, S. 603 - 608Online Volltext: dx.doi.org/ (Open Access)
-
Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC) : First safety results from the randomized CARIN trial.In: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 1044Online Volltext: dx.doi.org/
-
Improving chemotherapy capacity by switching from intravenous to oral vinorelbine : TAMINO, an international time and motion auditIn: Lung Cancer Jg. 67 (2010) Nr. Suppl. 1, S. S4Online Volltext: dx.doi.org/
-
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanesIn: Cancer Chemotherapy and Pharmacology Jg. 65 (2010) Nr. 4, S. 755 - 763Online Volltext: dx.doi.org/
-
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphomaIn: Journal of Cancer Research and Clinical Oncology Jg. 135 (2009) Nr. 3, S. 459 - 466Online Volltext: dx.doi.org/
-
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomasIn: European Journal of Haematology Jg. 78 (2007) Nr. 2, S. 93 - 101Online Volltext: dx.doi.org/
-
Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphomaIn: Tumori Journal (TJ) Jg. 93 (2007) Nr. 5, S. 409 - 416Online Volltext: dx.doi.org/
-
Response of pseudomyxoma peritonei to gemcitabineIn: Acta Oncologica Jg. 45 (2006) Nr. 1, S. 98 - 100Online Volltext: dx.doi.org/
-
1L maintenance therapy in patients with newly diagnosed advanced or metastatic ovarian cancer in routine care in Germany : results from the German registry platform SMARAGD
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie. 13. bis 16. Oktober 2023, Hamburg,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 152 - 153Online Volltext: dx.doi.org/ (Open Access) -
68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S265Online Volltext: dx.doi.org/ (Open Access) -
Routine care of early breast cancer (stage I-III) in Germany : Data of the prospective, intersectoral research platform OPAL
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO): SEP 09-13, 2022; Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S622Online Volltext: dx.doi.org/ (Open Access) -
SMARAGD : die prospektive, nationale Registerplattform zur Untersuchung von Behandlungsrealität, Wirksamkeit und Erkrankungsverlauf von Patientinnen mit Ovarial- oder Endometriumkarzinom in Deutschland
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 72Online Volltext: dx.doi.org/ (Open Access) -
Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line : Data from the registry platform OPAL
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO): SEP 09-13, 2022; Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. 643 - S644Online Volltext: dx.doi.org/ (Open Access) -
Early metabolic evaluation using F-18-FDG PET/CT might help to identify patients who benefit from treatment with cdk4/6 inhibitors
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 121 - 122Online Volltext: dx.doi.org/ (Open Access) -
Palbociclib in combination with letrozole as first- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany : Interim results of the INGE-B phase 2 study
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 299Online Volltext: dx.doi.org/ (Open Access) -
Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer : Final results from the randomized phase II trial VicTORia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 158 - 159Online Volltext: dx.doi.org/ (Open Access) -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19Online Volltext: dx.doi.org/ (Open Access)
-
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment Jg. 36 (2013) Nr. Suppl. 7, S. 157Online Volltext: dx.doi.org/ -
Optimierung der Therapie des metastasierten MammakarzinomsDuisburg ; Essen (2021) 1 CD-ROM
-
Use of newly approved drugs for patients with early breast cancer (stage I-III) in Germany - data of the prospective, intersectoral research platform OPAL
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 167 - 168Online Volltext: dx.doi.org/ (Open Access) -
Behandlungsrealität des frühen Mammakarzinoms (Stadium I-III) in Deutschland : Daten aus der prospektiven, intersektoralen Registerplattform OPAL
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 211Online Volltext: dx.doi.org/ (Open Access) -
Second-line Therapien von Patientinnen mit frühem Progress unter CDK4/6-Inhibitoren in der first-line : Daten aus der deutschen Registerplattform OPAL
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 107Online Volltext: dx.doi.org/ (Open Access) -
Tucatinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem HER2+ Mammakarzinom, die zuvor mit mindestens zwei anti-HER2-basierten Therapieregimen behandelt wurden : Studiendesign der nicht-interventionellen Studie TRACE
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 210Online Volltext: dx.doi.org/ (Open Access) -
Implementation of new tests and treatments for patients with advanced triple negative breast cancer in routine care : data from the registry platform OPAL
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 246Online Volltext: dx.doi.org/ (Open Access) -
Rare patients in routine care : Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL
San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020; San Antonio, Texas,In: Cancer Research Jg. 81 (2021) Nr. 4, Supplement, S. PS11 - 16Online Volltext: dx.doi.org/